䠄䠒䠅㻌 㻌
BNCT 䛾䛯䜑䛾 3 ḟඖ䝀䝹⥺㔞ィ䛾୰ᛶᏊ⥺䛻ᑐ䛩䜛ᛂ⟅≉ᛶ 䛻㛵䛩䜛◊✲㻌
㻌 ᗈᓥᅜ㝿Ꮫಖ་⒪Ꮫ㒊㻌 㻌 ᯘ㻌ៅ୍㑻㻌 㻌 ி㒔Ꮫ」ྜཎᏊຊ⛉Ꮫ◊✲ᡤ㻌 Ḉ㻌 Ⰻ᠇㻌 㻌 ㏆␥ᏛཎᏊຊ◊✲ᡤ㻌 ⱝᯘ㻌 ※୍㑻㻌 㻌
䠍 䠍䠊䠊㻌㻌ᗎᗎ㻌㻌
㻌 䝩䜴⣲୰ᛶᏊᤕᤊ⒪ἲ䠄Boron Neutron Capture Therapy㻌௨ୗ㻌BNCT䠅䛿䠈⇕୰ᛶᏊ㻌 㻔䠘0.5eV㻕㻌 䜢ᤕ⋓䛧䛯䝩䜴⣲ཎᏊ᰾㻔10B㻕䛜ḟᘧ䛾䜘䛖䛻䝦䝸䜴䝮ཎᏊ᰾䠄Į⢏Ꮚ䠅䛸㊴䝸䝏䜴䝮ཎᏊ᰾䛻ศ䛩 䜛⌧㇟䜢⏝䛩䜛䠊㻌
n + 10%ĺ11%ĺ4He + 7Li㻌 㻌 䠄䛒䜛䛔䛿㻌10B(n,Į7Li㸧
䛣䛾ᛂ䛜⭘⒆⣽⬊ෆ䛷⏕䛨䛯ሙྜ䠈⣽⬊㻝ಶ⛬ᗘ䛾㡿ᇦ䠄⣙ȝP䠅䛻䛭䛾㐠ື䜶䝛䝹䜼䞊䜢䛶 ᨺฟ䛩䜛䛾䛷䠄㧗LET䠅䠈㧗䛔ẅ⣽⬊ຠᯝ䛜ᚓ䜙䜜䜛䠊䝩䜴⣲㻔10B㻕䛿䠈๓䛻⭘⒆⣽⬊䛻㞟✚䛧䜔䛩 䛔ᛶ㉁䜢ᣢ䛴䝩䜴⣲ྜ≀䛸䛧䛶ᝈ⪅䛻ᢞ䛥䜜䠈䛭䛾ᚋᝈ㒊䛻୰ᛶᏊ⥺䛜↷ᑕ䛥䜜䜛䠊䛭䛾⤖ᯝ䠈
ୖグ䛾᰾ศᛂ䛜⏕䛨䠈䛭䛾⣽⬊䜢Ṛ⁛䛥䛫䜛䠊ᨺฟ䛥䜜䜛Į⢏Ꮚ➼䛿㣕⛬䛜ᩘȝP䛸▷䛔䛾䛷⒴
⣽⬊࿘ᅖ䛾ṇᖖ⤌⧊䜈䛾ᦆയ䜢䜋䛸䜣䛹䛘䛪䛻⒴⣽⬊䛾䜏䜢Ṛ⁛䛥䛫䜛䛣䛸䛜ྍ⬟䛷䛒䜚䠈ᚋ 䛾Ⓨᒎ䛜ᮇᚅ䛥䜜䛶䛔䜛䠊䛧䛛䛧䠈BNCT䛻䛚䛔䛶䛘䜙䜜䜛⥺㔞䛿ୖグ䛾ᛂ䛻㉳ᅉ䛩䜛⥺㔞䠄䝩 䜴⣲⥺㔞䠅௨እ䛻ཎᏊ⅔䛛䜙䛾䜺䞁䝬⥺䜔⏕యෆ䛾ᵝ䚻䛺ඖ⣲䛸୰ᛶᏊ䛸䛾ᛂ䛻㉳ᅉ䛩䜛㊴
᰾䜔༶Ⓨ䜺䞁䝬⥺䛺䛹䛾㠀䝩䜴⣲⥺㔞䜒ྵ䜣䛷䛚䜚䠈䛣䜜䜙䛾ศᕸ䜢ṇ䛧䛟ホ౯䛩䜛䛣䛸䛿ᮍ䛰ᐜ᫆
䛷䛿䛺䛔䠊㻌
㻌 䛭䛾୍᪉䛷䠈⢏Ꮚ⥺⒪㻔PT㻕䜔ᙉᗘኚㄪᨺᑕ⥺⒪㻔IMRT㻕➼䠈┠ⓗ䛾ᕢ䛻⥺㔞䜢㞟୰䛥䛫䜛 㧗⢭ᗘᨺᑕ⥺⒪䛜ྍ⬟䛸䛺䛳䛶䛝䛶䛔䜛䛣䛸䛻క䛔䠈⒪ィ⏬䜔⥺㔞ホ౯䛻䛚䛔䛶䛭䛾㻟ḟඖ⥺
㔞ศᕸ䜢┤᥋ ᐃ䛷䛝䜛⥺㔞ィ䛾㛤Ⓨ䛜ồ䜑䜙䜜䛶䛔䜛䠊㏆ᖺ䠈䛭䛾ೃ⿵䛾୍䛴䛸䛧䛶㻟ḟඖ䝀䝹
⥺㔞ィ䛜ὀ┠䜢㞟䜑䛶䛔䜛[1]䠊㻟ḟඖ䝀䝹⥺㔞ィ䛿ᨺᑕ⥺↷ᑕ䛻䜘䛳䛶⏕䛨䜛Ỉศゎ䝷䝆䜹䝹䛻䜘 䜛Ꮫᛂ䜢⏝䛧䛯Ꮫ⥺㔞ィ䛾୍⩌䛷䛒䜛䠊௦⾲ⓗ䛺㻟ḟඖ䝀䝹⥺㔞ィ䛸䛧䛶䛿䠈Ỉ⁐ᾮ୰䛻 䛚䛡䜛䝡䝙䝹䝰䝜䝬䞊䠄C=C㻌ᇶ䜢ྵ䜐᭷ᶵศᏊ䠅䛾䝷䝆䜹䝹㔜ྜᛂ䠄㧗ศᏊ䛾⏕ᡂ䠅䜢⏝䛧䛯䝫 䝸䝬䞊䝀䝹⥺㔞ィ䜔䠈㕲䛾㓟ᛂ䠄Fe2+ ĺ Fe3+䠅䜢⏝䛧䛯䝣䝸䝑䜿䝀䝹⥺㔞ィ䠈䛚䜘䜃ᨺᑕ⥺ឤ
ཷᛶⰍ⣲䜢⏝䛧䛯Ⰽ⣲䝀䝹⥺㔞ィ䛜▱䜙䜜䛶䛔䜛䠊䛣䜜䜙䛾ᛂ⏕ᡂ≀䛿Ỉ⁐ᾮ୰䛷䛿↷ᑕᚋ䠈 ᣑᩓ䜔ỿẊ䛻䜘䜚䛭䛾✵㛫ሗ䛜ᾘኻ䛧䛶䛧䜎䛖䛾䛷䠈䛭䛾Ỉ⁐ᾮ䜢䝊䝷䝏䞁➼䛾䝀䝹䛻䜘䜚ᅛ
䛩䜛䛣䛸䛻䜘䜚䛭䛾✵㛫ሗ䜢ಖᣢ䛧䛶䛔䜛䛾䛜≉ᚩ䛷䛒䜛䠊䛭䛾ᛂ䛻䜘䜛ኚ䜢᰾☢Ẽඹ㬆⏬
ീ⨨䠄MRI䠅䜔ගᏛCT➼䛷ㄞ䜏ྲྀ䜛䛣䛸䛻䜘䜚྾⥺㔞䛾㻟ḟඖศᕸ䜢┤᥋ồ䜑䜛䛣䛸䛜䛷䛝䜛䠊 䜎䛯䠈䛭䛾⤌ᡂ䛿90䠂๓ᚋ䛜Ỉ䛷䛒䜛䛛䜙Ỉ䠄⏕య䠅➼౯䛸䜏䛺䛩䛣䛸䛜䛷䛝䠈⏕య䛻ᑐ䛩䜛྾
⥺㔞 ᐃ䛻㐺䛧䛶䛔䜛䠊㻌
㻌 ➹⪅䜙䛿䛣䜜䜎䛷䠈䛣䜜䜙䛾㻟ḟඖ䝀䝹⥺㔞ィ䜢䛻㼄⥺䠄䜺䞁䝬⥺䠅䜔㝧Ꮚ⥺䞉Ⅳ⣲⥺䛻㐺⏝䛧䠈
≉ᛶホ౯䛸ᨵⰋ䠈䛚䜘䜃⮫ᗋ䜈䛾ᛂ⏝䛻ྲྀ䜚⤌䜣䛷䛝䛯[2, 3]䠊୍᪉䠈㻟ḟඖ䝀䝹⥺㔞ィ䛾BNCT䠄୰
ᛶᏊ⥺䠅䜈䛾㐺⏝䛿䠈ୡ⏺ⓗ䛻ぢ䛶䜒ཎᏊ⅔䛾⏝䛜㝈䜙䜜䜛䛣䛸䠈䜎䛯䛥䜙䛻䛿BNCT䛻ྲྀ䜚⤌䜣 䛷䛔䜛ᅜ⮬య䛜ᑡ䛺䛔䛣䛸䛺䛹䛛䜙䛭䛾ሗ࿌䛿ᮍ䛰ᑡᩘ䛻䛸䛹䜎䛳䛶䛔䜛㻌[4, 5]䠊㻌
㻌 ᮏ◊✲䛷䛿䛣䜜䜎䛷䛻ᘬ䛝⥆䛝䠈Ỉ⁐ᾮ୰䛻䛚䛡䜛䝫䝸䝡䝙䝹䜰䝹䝁䞊䝹(PVA)䛸ᨺᑕ⥺↷ᑕ䛻䜘 䜚⏕䛨䛯䝫䝸䝶䜴⣲㻔I3í➼㻕䛸䛾㘒యᙧᡂ䛻䜘䜛ⓎⰍ䠄㉥Ⰽ䠅䜢⏝䛧䛯䝷䝆䜸䜽䝻䝭䝑䜽䝀䝹⥺㔞ィ
(PVA-I 䝀䝹⥺㔞ィ)䛾㛤Ⓨ䜢⾜䛳䛶䛝䛯䠊䛣䛾⥺㔞ィ䛿䠈↷ᑕ๓䛿↓Ⰽ㏱᫂䛷䛒䜛䛜䠈Ỉ⁐ᾮ䛻ྵ
䜎䜜䜛䝶䜴⣲䜲䜸䞁㻌 㻔,䌦䛜䠈ᨺᑕ⥺↷ᑕ䛻䜘䛳䛶⏕䛨䛯OH䝷䝆䜹䝹➼(R䞉)䛾Ỉศゎ䝷䝆䜹䝹䛻䜘䜚㓟
䛥䜜䛶㻌I3í䜢⏕䛨䠈䛣䜜䛜PVA 䛾ᮍ䜿䞁㒊䠄㓑㓟ᇶ㻦㻌CH3COOí䠅䛸」ྜయ䠄㟁Ⲵ⛣ື㘒య䠅䜢 ᙧᡂ䛩䜛䛣䛸䛻䜘䜚㉥䛟ⓎⰍ䛩䜛䠊㻌
H2O ĺ R䞉 (Radiolysis)
3Ií (+ R䞉) ĺ I2+ Ií ĺ I3í (Oxidation)
PVA + I3í ĺ PVA-I (Complexation, colored)
䛣䛾Ỉ⁐ᾮ䜢ᅛ䠄䝀䝹䠅䛩䜛䛯䜑䠈ᖺᗘ䛿Ꮫⓗᯫᶫ䠄䜾䝹䝍䝹䜰䝹䝕䝠䝗㻔GTA)䠅䜢⏝䛔
䛯 PVA-GTA-I 䝀䝹⥺㔞ィ䜢㛤Ⓨ䛧䠈ప䜶䝛䝹䜼䞊(150 kV)X⥺䜢⏝䛔䛶ᇶ♏⥺㔞≉ᛶ䜢ㄪ䜉䠈
䛭䛾᭷⏝ᛶ䜢♧䛧䛯䠊
ᮏᖺᗘ䛿䜎䛪䠈PVA-GTA-I 䝀䝹⥺㔞ィ䛾ཎᏊ⅔↷ᑕ䛻ᑐ䛩䜛ᛂ⟅≉ᛶ䜢ㄪ䜉䛯䠊䜎䛯䠈⇕୰ᛶ Ꮚቑឤ䛸䛧䛶㻌6Li 䜢ῧຍ䛧䛯ሙྜ䛾ప䜶䝛䝹䜼䞊X⥺䛻ᑐ䛩䜛ᛂ⟅≉ᛶ䛾ホ౯䛸䠈ཎᏊ⅔䛛䜙䛾
୰ᛶᏊ↷ᑕ䛻䛚䛡䜛㻌6Li 䛾ቑឤຠᯝ䜢ㄪ䜉䛯䠊ຍ䛘䛶䠈᭦䛺䜛㧗ឤᗘ䜢┠ⓗ䛸䛧䛶᪂つ䛾ቑឤ
㻌(KNO3)㻌䜢᳨ウ䛧䛯䠊㻌 㻌
䠎
䠎䠊䠊㻌㻌ᐇᐇ㦂᪉ἲ㻌㻌 䠎
䠎䠊䠊䠍䠍㻌㻌ヨヨᩱ㻌㻌
㻌 ᮏ◊✲䛷స〇䛧䛯㻌PVA-GTA-I 䝀䝹⥺㔞ィ䛿䠈⾲⾲㻝㻝䛻♧䛩䜘䛖䛻䠈㒊ศ䜿䞁ᆺPVA 㻔䜿䞁ᗘ
⣙86-90 mol%) 䛸䠈䝶䜴⣲※䛸䛧䛶䛾䝶䜴䜹䝸䜴䝮㻔KI㻕䠈㑏ඖ䛸䛧䛶䝣䝹䜽䝖䞊䝇㻔Fructose㻕䠈PVA䜢 䝀䝹䛩䜛䛯䜑䛾Ꮫⓗᯫᶫ䛸䛧䛶䜾䝹䝍䝹䜰䝹䝕䝠䝗(GTA)䠈ᯫᶫᛂ䜢ಁ㐍䛩䜛㓟Ⓨ⏕䛸䛧 䛶䛾䜾䝹䝁䝜䝕䝹䝍䝷䜽䝖䞁(GDL)䠈䛚䜘䜃⁐፹䛸䛧䛶䛾Ỉ䛛䜙䛺䜛䠄ᶆ‽⤌ᡂ/standard䠅䠊ᮏᖺᗘ䛿䠈 ᶆ‽⤌ᡂ䛻⇕୰ᛶᏊቑឤ䛸䛧䛶㻌6Li2SO4㻌䜢ῧຍ䛧䛯䝀䝹䜢స〇䛧䠈ཎᏊ⅔↷ᑕ䛻䛚䛡䜛⥺㔞ᛂ
⟅䛻ᑐ䛩䜛䛭䛾ຠᯝ䜢ㄪ䜉䛯䠊୍᪉䠈ᨺᑕ⥺↷ᑕ䛻䜘䛳䛶⏕䛨䜛Ỉ㟁Ꮚ㻔eaq䇷㻕䛿䠈ྠ䛨䛟ᨺᑕ⥺䛻 䜘䜛Ỉศゎᛂ䛻䜘䛳䛶⏕ᡂ䛩䜛 OH㻌䝷䝆䜹䝹䛻䜘䜚㓟䛥䜜䛶⏕ᡂ䛩䜛䝶䜴⣲䝷䝆䜹䝹㻌 㻔㻵䞉㻕㻌䛸
⤖ྜ䛧䠈I3í㻌䛾⏕ᡂ䜢㜼ᐖ䛩䜛䛣䛸䛜▱䜙䜜䛶䛔䜛䠊㻌
Ií (+ R䞉) ĺ I䞉 (Oxidation)
I䞉 + eaq䇷 ĺ Ií (Recombination)
䛭䛣䛷ᶆ‽⤌ᡂ䛻Ỉ㟁Ꮚᤕᤊ䛸䛧䛶㻌KNO3㻌䜢ῧຍ䛩䜛䛣䛸䜢᳨ウ䛧䛯䠊స〇䛧䛯䝀䝹䛿 PMMA 〇䛾ගᏛ䝉䝹䠄䜻䝳䝧䝑䝖䠈㻌ෆᑍ 10×10×45 mm3䠅䛻ᑠศ䛡䛧䛶ᑒධ䛧䛯䠊స〇ᚋ䠈ᜏ ᗜ 䠄ႏ䠅䛷୍ᬌຍ 䛧䠈ᯫᶫ䞉ึᮇ䠄ᾘⰍ䠅䛥䛫䛯䠊
㻌 䠎
䠎䠊䠎㻌㻌↷↷ᑕ㻌㻌 䠎
䠎䠊䠎㻚㻚㻌䠍䠍㻌㻌 150 kV-X⥺⥺↷↷ᑕ㻌㻌
㻌 X⥺↷ᑕ䛿㏆␥ᏛཎᏊຊ◊✲ᡤ䛾㼄⥺Ⓨ⏕⨨䠄᪥❧㻌MBR-1520R-3䠅䛛䜙ᚓ䜙䜜䜛X⥺䜢⏝
䛔䛯䠊ᅇ䛿⟶㟁ᅽ㻔Vp㻕䜢㻌150 kV䠈⟶㟁ὶ㻔A㻕䛿㻌20 mA䠈⥺㔞⋡㻌3 Gy/min㻌䛻ᅛᐃ䛧䠈0 – 20 Gy㻌䛻ᑐ䛩䜛⥺㔞ᛂ⟅≉ᛶ䜢ㄪ䜉䛯䠊㻌㻌
䠎
䠎䠊䠎㻚㻚㻌䠎䠎㻌㻌 ୰୰ᛶᏊ↷↷ᑕ㻌㻌
㻌୰ᛶᏊ⥺↷ᑕ䛿䠈㏆␥ᏛཎᏊຊ◊✲ᡤ䛾ᩍ⫱⏝ཎᏊ⅔䠄UTR-KINKI䠅୰ኸ䝇䝖䝸䞁䜺䞊䛻䛶
⾜䛳䛯䠊⥺㔞ィ䜢䜰䝹䝭〇䝣䝺䞊䝮䛻ᅛᐃ䛧䠈ฟຊ1 W㐠㌿䛻㻥㻜ศ䛚䜘䜃㻝㻤㻜ศ䛾↷ᑕ䜢⾜䛳䛯䠊㻌 㻌
Table 1: The composition of PVA-GTA-I gels. (For convenience, the molarity per 1000 g of water is represented by M in this report.)
䠎
䠎䠊䠊䠏䠏㻌㻌 ᐃ㻌㻌
⥺㔞ᛂ⟅䛾ホ౯䛿䠈↷ᑕ䛾⩣᪥䠈ᗈᓥᅜ㝿Ꮫ䛾⣸እྍどศගගᗘィ䠄ᓥὠ㻌UV-1600PC䠅䜢
⏝䛔䛶350-800 nm䛾⠊ᅖ䛷྾ගᗘ䠄Abs.䠅䛾 ᐃ䜢⾜䛳䛯䠊ཧ↷ヨᩱ䛻䛿⣧Ỉ䜢⏝䛔䠈↷ᑕ䛥䜜䛯
ヨᩱ䛾⥺㔞ᛂ⟅䛿᭱྾Ἴ㛗㻔Ȝmax= 490 nm㻕䛻䛚䛡䜛ᮍ↷ᑕ䛾ヨᩱ䛻ᑐ䛩䜛྾ගᗘ䠄ǻ$EV.䠅䛷 ホ౯䛧䛯䠊㻌
ǻ$EV $EVL– Abs.(n)
䛣䛣䛷䠈Abs.(i)㻌䛸Abs.(n)㻌䛿䛭䜜䛮䜜↷ᑕ䛥䜜䛯䝀䝹⥺㔞ィ䛚䜘䜃ᮍ↷ᑕ䛾䝀䝹⥺㔞ィ䛾྾ගᗘ 䛷䛒䜛䠊㻌
㻌 䠏
䠏㻚㻚㻌㻌⤖⤖ᯝ䞉⪃ᐹ㻌㻌
ཎᏊ⅔↷ᑕ䛥䜜䛯㻌6Li㻌䜢ྵ䜐㻌PVA-GTA-I㻌䝀䝹⥺㔞ィ䜢㻌Fig.1 䛻♧䛩䠊྾⥺㔞䠄↷ᑕ㛫䠅 䛻ᛂ䛨䛶䠈䜎䛯㻌6Li㻌⃰ᗘ䛾㧗䛔䜒䛾䜋䛹ⓎⰍ䛜⃰䛟䛺䛳䛶䛔䜛䛾䛜┠ど䛷䜒ศ䛛䜛䠊㻌 㻌
Fig.2(left) 䛿䛭䜜䜙䛾྾ගᗘ䛾ኚ䜢♧䛧䛶䛔䜛䠊䛣䜜䛻䜘䜚PVA-GTA-I䝀䝹⥺㔞ィ䜈䛾㻌6Li㻌䛾
ῧຍ䛜⇕୰ᛶᏊ⥺䛾ቑឤ䛻᭷ຠ䛷䛒䜛䛣䛸䛜☜ㄆ䛷䛝䛯䠊㻌
䜎䛯䠈Fig.2(right)㻌䛻䛿䛭䜜䜙䛾⥺㔞ィ䛾㻌150 kV-X⥺↷ᑕ䛧䛯ሙྜ䛾⥺㔞ᛂ⟅䜢♧䛩䠊ప䜶䝛 䝹䜼䞊X⥺䠄ගᏊ⥺䠅䛻ᑐ䛧䛶䛿䠈ῧຍ䛧䛯㻌6Li 䛾ᙳ㡪䛿↓ど䛷䛝䜛䛣䛸䛜♧䛥䜜䛯䠊㻌
Base solution
Water 90 wt%
PVA 10 wt%
Additive
KI 100 mM
Fructose 100 mM
GTA 10 mM
GDL 100 mM
Sensitizer
6Li2SO4 0, 25, 50 mM
KNO3 0, 100 mM
୍᪉䠈ᶆ‽⤌ᡂ䛾㻌PVA-GTA-I㻌䝀䝹⥺㔞ィ䛻Ỉ㟁Ꮚᤕᤊ䛸䛧䛶㻌KNO3㻌䜢ῧຍ䛧䛯ሙྜ䛾㻌
150 kV-X⥺䛻ᑐ䛩䜛⥺㔞ᛂ⟅䜢 Fig.3㻌䛻♧䛩䠊KNO3㻌䛾ῧຍ䛻䜘䜚ᛂ⟅ឤᗘ䛜⣙㻟ಸቑຍ䛩䜛䛣䛸
䛜♧䛥䜜䛯䠊㻌
ᚋ䠈䛥䜙䛻⤌ᡂ䛾᭱㐺䛸䠈✚⟬䞉⥺㔞⋡౫Ꮡᛶ䜔㛫䞉✵㛫Ᏻᐃᛶ➼䛾ᇶ♏≉ᛶ䛾ホ౯䜢
⾜䛔䠈᭱⤊ⓗ䛻䛿PVA-GTA-I䝀䝹⥺㔞ィ䛻ᑐ䛩䜛୰ᛶᏊ䝡䞊䝮䛾ᛂ⟅䜢ㄪ䜉䛶䛔䛟ணᐃ䛷䛒䜛䠊
㻌㻌 㻌㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌 㻌㻌
Figure 1㻌㻌 PVA-GTA-I gel dosimeters containing 6Li irradiated in the reactor for 0, 90, and 180 min.
㻌㻌
㻌㻌 㻌㻌
Figure 2㻌㻌 Dose responses of the PVA-GTA-I gel dosimeters containing different concentration of 6Li irradiated (left) by the reactor, and (right)by the 150 kV-X-ray, respectively.
㻌㻌
Figure 3㻌㻌 Dose responses of the PVA-GTA-I gel dosimeters with and without KNO3irradiated by the 150 kV-X-ray.
ཧ
ཧ⪃ᩥ⊩㻌㻌
[1] e.g. “Proceedings of International Conference on 3D Radiation Dosimetry (IC3DDose)”, J. Phys. : Conf. Ser.,847(2017), 573(2015),444(2012),250(2010),164(2009).
[2] Hayashi S et al, 2010.Radiat. Phys. Chem.79(7) 803-808.
[3] Hayashi S et al, 2012,Radiat. Phys. Chem.81(7) 884-888.
[4] Uusi-Simola J et al, 2007,J. Appl. Clin. Med. Phys.8114–23.
[5] Gambarini G et al, 2010,Radiat. Meas.45 í.
㻌㻌 ᴗ
ᴗ⦼୍ぴ㻌㻌
䞉 Hayashi S et al., 2020, "Novel radiochromic gel dosimeter based on a polyvinyl alcohol-iodide complex" Radiat. Meas.131106226
䞉 Hayashi S et al., 2019 "Influence of the components of a radiochromic PVA-Iodide gel dosimeter on the optical dose response" J. Phys.: Conf. Ser.1305012031
䞉 Hayashi S et al., "Development of novel radiochromic gel dosimeter based on polyvinyl alcohol- iodide complex for clinical three-dimensional dosimetry" The 9th International Meeting on Halogen Chemistry (HALCHEM IX) (Perugia, Italy, 2019.9.23-26)
䞉 Hayashi S et al., "Improvement of the transparency in a PVA-iodide radiochromic gel dosimeter", The 19th International Conference on Solid State Dosimetry (SSD19) (Hiroshima, Japan, 2019.9.15-20)
䞉 Hayashi S et al., "Improvement of the transparency and the temporal stability using sucrose in a polyvinyl alcohol-iodide radiochromic gel dosimeter", 16th International Congress of Radiation Research (ICRR2019) (Manchester, UK, 2019.8.25-29)
㻌 㻌 㻌 㻌
